Point72 Asset Management L.P. Purchases New Stake in Atyr PHARMA INC (NASDAQ:ATYR)

Point72 Asset Management L.P. purchased a new stake in Atyr PHARMA INC (NASDAQ:ATYR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,883,197 shares of the company’s stock, valued at approximately $17,677,000. Point72 Asset Management L.P. owned 5.82% of Atyr PHARMA as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in Atyr PHARMA by 467.8% in the fourth quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company’s stock valued at $646,000 after buying an additional 147,092 shares during the period. Dimensional Fund Advisors LP purchased a new position in Atyr PHARMA in the fourth quarter valued at approximately $881,000. Charles Schwab Investment Management Inc. purchased a new position in Atyr PHARMA in the fourth quarter valued at approximately $144,000. Raymond James Financial Inc. purchased a new position in Atyr PHARMA in the fourth quarter valued at approximately $39,000. Finally, Wells Fargo & Company MN purchased a new position in Atyr PHARMA in the fourth quarter valued at approximately $383,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Stock Performance

NASDAQ:ATYR opened at $3.27 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The firm has a 50-day moving average of $3.27 and a two-hundred day moving average of $3.40. The stock has a market cap of $291.04 million, a P/E ratio of -3.48 and a beta of 0.79. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. On average, research analysts expect that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ATYR has been the topic of several research reports. Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research note on Friday, March 14th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.